Surgical treatment of hepatocellular carcinoma in the era of COVID-19 pandemic: A comprehensive review of current recommendations

Table 2 Studies reporting on the surgical treatment of hepatocellular carcinoma in the pre-coronavirus disease and coronavirus disease era

Ref.	Treatment of HCC
Aghemo et al[18]	Surgical and nonsurgical locoregional procedures for management of HCC had been reduced (44% and 34%, respectively) or suspended (44% and 8%, respectively) in the centers involved in the study
Amaddeo et al[4]	Delay was longer than one month in the treatment of HCC in 2020, compared to 2019 (pre-COVID era)
Balakrishnan et al[13]	Only 10% of respondents in a cross-sectional survey reported that cancer surgery for HBP proceeded unaffected in the pandemic
Iavarone et al[63]	In a 4-wk period in 2020 compared with a 4-wk period in 2019, a lower number of patients submitted to surgical resection and liver transplant was observed
Siniscalchi et al[64]	Transplantation activities were reduced from February June 30, 2020, compared with the corresponding period in 2019
Soin et al[65]	In the period March-June 2020 the authors performed less living-donor liver transplantation than 2019 (39 vs 23)

HCC: Hepatocellular carcinoma; COVID-19: Coronavirus disease 2019; HPB: Hepato-pancreato-biliary.